SII informs Centre it will supply around 200 mn Covishield doses in Sep

SII has informed the Centre that it will be able to supply around 20 crore doses of COVID-19 vaccine Covishield in September itself to Government to India and private hospitals, official sources said

Covishield
Covishield (Photo: Reuters)
Press Trust of India New Delhi
2 min read Last Updated : Aug 26 2021 | 5:39 PM IST

Serum Institute of India (SII) has informed the Centre that it will be able to supply around 20 crore doses of COVID-19 vaccine Covishield in September itself to Government to India and private hospitals, official sources said.

The Pune-based SII has already supplied 12 crore doses of the COVID-19 vaccine in August, they said.

Director, Government and Regulatory Affairs at SII, Prakash Kumar Singh has communicated to the Union Health Ministry that the firm has further enhanced its production capacity and it will be able to supply approximately 20 crore doses of Covishield in September itself to Government of India and private hospitals, an official source said.

In a production plan submitted to the Centre in May, SII's director had communicated that the production of Covishield would be ramped up to 10 crore each in August and September, sources had said.

Later in May-end, Singh communicated to Union Home Minister Amit Shah that Covishield production would be ramped up to 10 crore doses in June.

"We are committed to enhancing the production capacity of our Covishield vaccine and have been working round-the-clock in spite of various challenges being faced by us because of COVID-19 pandemic.

"We are pleased to inform that in the month of June we will be able to manufacture and supply nine to 10 crore doses of our Covishield vaccine to our country as compared to our present production capacity of 6.5 crore doses in May," he had said in a communication to Shah.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Serum Institute of IndiaCoronavirus VaccineAstraZenecaVaccination

First Published: Aug 26 2021 | 5:38 PM IST

Next Story